AVMET-VLD 500

Description

AVMET-VLD 500 represents a potent combination therapy for individuals with type 2 diabetes when diet and exercise plus the single use of Metformin or Vildagliptin is not sufficient for glycemic control. Vildagliptin, a selective inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme, works by enhancing the levels of active incretin hormones, which inhibit glucagon release and stimulate insulin secretion in a glucose-dependent manner. This action results in the regulation of glucose levels in the blood, especially after eating.